Literature DB >> 15278448

Anti-hepatitis B surface antigen IgG1 subclass is predominant in individuals who have recovered from hepatitis B virus infection, chronic carriers, and vaccinees.

Lina Wang1, Shyh-Jye Lin, Ju-Hsin Tsai, Chung-Hung Tsai, Chung-Chuan Tsai, Chi-Chiang Yang.   

Abstract

Patterns of each IgG-specific subclass for hepatitis B virus (HBV) core antigen (anti-HBc) are remarkably different among individuals with different infection status, i.e., completely recovered or chronic carrier. Each of the IgG-specific subclasses of HBV surface antigen (anti-HBs) was tested for ELISA sensitivity using four commercially available hepatitis B surface antigen (HBsAg) kits and one self-prepared plate. The specificity in 18 serum samples obtained from chronic HBV carriers, recovered individuals, vaccinees and non-infected individuals was investigated. Differences in absorbance values were obtained by comparing results from these different plates. Data on the absorbance values of anti-HBs IgG subclasses obtained indicated that one to four subjects had a false-negative or false-positive result using the four commercial plates. Only the self-prepared plate demonstrated 100% specificity and sensitivity for anti-HBs subclasses. Moreover, the results indicate that anti-HBs subclass IgG1 was predominant in cured patients, chronic carriers and vaccinees. The samples from both chronic carriers and vaccinees exhibited a significantly higher concentration of total IgG and IgG1 than samples in recovered individuals (P<0.05).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15278448     DOI: 10.1007/s00430-004-0225-2

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  22 in total

1.  IgG subclass distribution of anti-HBs antibodies following vaccination with cDNA HBsAg.

Authors:  R M Borzì; P Dal Monte; M C Honorati; A Facchini
Journal:  J Immunol Methods       Date:  1992-01-21       Impact factor: 2.303

2.  Subtype specificity of anti-HBs antibodies produced by human B-cell lines isolated from normal individuals vaccinated with recombinant hepatitis B vaccine.

Authors:  Mohammad Ali Shokrgozar; Fazel Shokri
Journal:  Vaccine       Date:  2002-05-22       Impact factor: 3.641

3.  The serology of chronic hepatitis B infection revisited.

Authors:  T Maruyama; A McLachlan; S Iino; K Koike; K Kurokawa; D R Milich
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

Review 4.  Immune recognition of viral antigens.

Authors:  I A Wilson; R L Stanfield; D A Jewell; J B Ghiara; D H Fremont; E A Stura
Journal:  Infect Agents Dis       Date:  1994 Apr-Jun

Review 5.  Lymphokine control of in vivo immunoglobulin isotype selection.

Authors:  F D Finkelman; J Holmes; I M Katona; J F Urban; M P Beckmann; L S Park; K A Schooley; R L Coffman; T R Mosmann; W E Paul
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

6.  Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.

Authors:  M A Rico; J A Quiroga; D Subirá; S Castañón; J M Esteban; M Pardo; V Carreño
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

7.  Immunoglobulin G subclasses of antibodies to hepatitis B core antigen in HBs antigen positive liver diseases.

Authors:  S M Akbar; N Horiike; M Onji; Y Ohta
Journal:  J Gastroenterol Hepatol       Date:  1991 Jan-Feb       Impact factor: 4.029

8.  Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice.

Authors:  Kiminori Kimura; Kazuhiro Kakimi; Stefan Wieland; Luca G Guidotti; Francis V Chisari
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

9.  Comparison of class and subclass distribution of antibodies to the hepatitis B core and B e antigens in chronic hepatitis B.

Authors:  M Sällberg; H Norder; L O Magnius
Journal:  J Med Virol       Date:  1990-01       Impact factor: 2.327

10.  Cytokine gene polymorphisms in patients infected with hepatitis B virus.

Authors:  Ziv Ben-Ari; Eytan Mor; Orit Papo; Batia Kfir; Jaqueline Sulkes; Anat R Tambur; Ran Tur-Kaspa; Tirza Klein
Journal:  Am J Gastroenterol       Date:  2003-01       Impact factor: 10.864

View more
  3 in total

1.  Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen.

Authors:  D Huzly; T Schenk; W Jilg; D Neumann-Haefelin
Journal:  J Clin Microbiol       Date:  2008-02-06       Impact factor: 5.948

2.  Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine.

Authors:  Zhiqun Wang; Shu Zhang; Chao Luo; Qianzhen Wu; Qilan Liu; Yi-Hua Zhou; Yali Hu
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

3.  Diverse IgG subclass responses to adeno-associated virus infection and vector administration.

Authors:  Samuel L Murphy; Hojun Li; Federico Mingozzi; Denise E Sabatino; Daniel J Hui; Shyrie A Edmonson; Katherine A High
Journal:  J Med Virol       Date:  2009-01       Impact factor: 2.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.